Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Odronextamab, a CD20×CD3 bispecific antibody, demonstrated robust efficacy and durable responses, with a generally manageable safety profile, in patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the Phase 2 ELM-2 study. This exploratory analysis evaluated the prognostic value of minimal residual disease (MRD) status and tumor molecular profiles, based on circulating tumor DNA (ctDNA) analysis, for determining patient outcomes in ELM-2. Baseline and on-treatment ctDNA samples were used for MRD evaluation (AVENIO Oncology Assay Non-Hodgkin Lymphoma Test); baseline ctDNA samples were also used for molecular profiling. At data cutoff (March 24, 2025), the Cycle 4 Day 15 (C4D15) biomarker population with available ctDNA results comprised 60 patients with FL and 77 patients with DLBCL. Undetectable ctDNA at C4D15 was associated with prolonged progression-free survival (PFS) in the FL (hazard ratio [HR] 0.31, 95% confidence interval [CI]: 0.14-0.67) and DLBCL (HR 0.42, 95% CI: 0.24-0.75) cohorts. Combining undetectable ctDNA with achievement of PET-CT complete response at C4D15 was associated with extended PFS in both cohorts. Among patients with progressive disease per Lugano criteria, most had detectable ctDNA at C4D15 (FL, 15/19; DLBCL, 28/35). In the DLBCL cohort, LymphGen analysis by ctDNA showed that the MCD subtype trended towards shorter PFS, whereas the EZB subtype trended towards longer PFS, versus the rest of the cohort. MRD by ctDNA may be prognostic of outcomes with odronextamab in FL/DLBCL and could form the basis of response-guided treatment paradigms. This trial is registered at www.ClinicalTrials.gov as NCT03888105.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/bloodadvances.2025016332 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials.
J Immunother Precis Oncol
August 2025
The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.
Introduction: Patients with advanced solid tumors may be considered for early phase clinical trials investigating the safety, tolerability, and dosing of experimental therapies. Optimizing participant selection is critical to maximize clinical benefit and meet trial endpoints with fewer participants. One in six participants does not meet routine life expectancy requirements (>3 months), highlighting the need for improved prognostication.
View Article and Find Full Text PDFOlder Adult Participation in Early-Phase Lung Cancer Clinical Trials, 1998 to 2020.
JTO Clin Res Rep
October 2025
Division of Hematology/Oncology, Department of Medicine, University of California Davis, Sacramento, California.
Objectives: Despite advances, lung cancer treatment remains associated with substantial toxicity. Early-phase clinical trials inform the safety and efficacy of novel lung cancer treatments. Although older adults represent most patients with lung cancer, and they are underrepresented in phase 3 trials, age disparity in early-phase lung cancer trials is ill-defined.
View Article and Find Full Text PDFThe SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors.
PLoS One
September 2025
Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Background: Current aftercare in breast cancer survivors aims to detect local recurrences or contralateral disease, while the detection of distant metastases has not been a central focus due to a lack of evidence supporting an effect on overall survival. However, the data underpinning these guidelines are mainly from trials of the 1980s/1990s and have not been updated to reflect the significant advancements in diagnostic and therapeutic options that have emerged over the past 40 years. In this trial, the aim is to test whether a liquid biopsy-based detection of (oligo-) metastatic disease at an early pre-symptomatic stage followed by timely treatment can impact overall survival compared to current standard aftercare.
View Article and Find Full Text PDFCirculating Tumor DNA Profiling Identifies Actionable Mutations as Prognostic Markers in Advanced Neuroendocrine Tumors.
Neuroendocrinology
September 2025
Introduction Neuroendocrine tumors (NETs) are a rare and heterogeneous group of neoplasms with both clinical and genetic diversity. The clinical applicability of molecular profiling using liquid biopsy for identifying actionable drug targets and prognostic indicators in patients with advanced NETs remains unclear. Methods In this study, we utilized a custom-made 37 genes panel of circulating tumor DNA (ctDNA) based on next-generation sequencing (NGS) in 47 patients with advanced NETs.
View Article and Find Full Text PDFUSP44, ZNF454, and GPRC5B ctDNA Methylation Markers in Breast Cancer: Limited Clinical Relevance for Disease Monitoring and Tumor Characteristics.
Asia Pac J Clin Oncol
September 2025
Department of Surgery, School of Medicine, Daegu Catholic University, Daegu, Republic of Korea.
Purpose: This study aimed to identify breast cancer-specific circulating tumor DNA (ctDNA) methylation markers that correspond to tissue DNA methylation.
Methods: Using The Cancer Genome Atlas (TCGA) database, we selected breast cancer-specific DNA methylation markers. The methylation and expression patterns of candidate genes were analyzed in breast cancer cell lines and tissue samples.